Findings from this clinical trial suggest the complexity of TGF‐β1 in DKD and general blockade of TGF‐β signalling may not be a good therapeutic approach for DKD due to the diverse role of TGF‐β in renal inflammation and fibrosis.14 Here, TGFB1 is linked to diabetic kidney disease.